|
| |
BioPortfolio's Approved Drugs DatabaseCamptosarIrinotecan HydrochlorideDownload PDF containing detailed information.
Press Releases About Camptosar:
|
 |
| Surging Interest Drives Third Year Announcement of Probiotic Research Grants |
29th October, 2009 |
DANONE |
3. Building relationships with leading researchers and research institutions
and supporting collaboration research in the area of probiotics and
intestinal microbiota.
GPC
|
| Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report |
24th September, 2009 |
Reportlinker |
-- SERMS
The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type
|
| Harvard Medical School Continues Education About Benefits of Probiotics |
8th July, 2009 |
The Dannon Company, Inc. |
BOSTON, July 8 /PRNewswire/ -- An emerging body of scientific research about probiotics was presented today at the academic conference, "Protective Nutrients, Are They Here To Stay?" an
|
| Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer |
1st June, 2009 |
Keryx Biopharmaceuticals, Inc. |
KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic
|
| Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer |
31st May, 2009 |
Keryx Biopharmaceuticals, Inc. |
KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic
|
Companies working in the area of Camptosar from Bioportfolio's Biocorporate database : | |
| Company Name | |
Pharmacia is a top-tier global pharmaceutical company, with a leading agricultural subsidiary. Pharmacia have built a portfolio of outstanding products, led by key growth drivers: CELEBREX® (celecoxib...
www.pharmacia.com/ View full profile
| |
Pharmacia is a top-tier global pharmaceutical company, with a leading agricultural subsidiary. Pharmacia have built a portfolio of outstanding products, led by key growth drivers: CELEBREX® (celecoxib...
www.biotech.pharmacia.se/ View full profile
| |
Pharmacia is a top-tier global pharmaceutical company, with a leading agricultural subsidiary. We have built a portfolio of outstanding products, led by our key growth drivers: CELEBREX® (celecoxib...
www.pharmacia.com/ View full profile
| | →View more Camptosar related companies. |
This page has been viewed 25 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Camptosar across BioPortfolio, or for Camptosar Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
